Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy

Here, we discuss recent evidence that an absence of stromal Cav-1 expression in human breast cancers is a powerful single independent predictor of early disease recurrence, metastasis, and poor clinical outcome. These findings have now been validated in two independent patient populations. Important...

Full description

Saved in:
Bibliographic Details
Published in:Cell cycle (Georgetown, Tex.) Vol. 8; no. 11; pp. 1654 - 1658
Main Authors: Witkiewicz, Agnieszka K., Casimiro, Mathew C., Dasgupta, Abhijit, Mercier, Isabelle, Wang, Chenguang, Bonuccelli, Gloria, Jasmin, Jean-François, Frank, Philippe G., Pestell, Richard G., Kleer, Celina G., Sotgia, Federica, Lisanti, Michael P.
Format: Journal Article
Language:English
Published: United States Taylor & Francis 01.06.2009
Subjects:
Angiogenesis Inhibitors - therapeutic use
Binding
Biology
Bioscience
Breast Neoplasms - classification
Breast Neoplasms - diagnosis
Breast Neoplasms - therapy
Calcium
Cancer
Caveolin 1 - metabolism
Cell
Cycle
Female
Fibroblasts - metabolism
Fibroblasts - physiology
Humans
Landes
Organogenesis
Prognosis
Proteins
Risk
Stromal Cells - metabolism
Survival Analysis
Up-Regulation
ISSN:1538-4101, 1551-4005, 1551-4005
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here, we discuss recent evidence that an absence of stromal Cav-1 expression in human breast cancers is a powerful single independent predictor of early disease recurrence, metastasis, and poor clinical outcome. These findings have now been validated in two independent patient populations. Importantly, the predictive value of stromal Cav-1 is independent of epithelial marker status, making stromal Cav-1 a new "universal" or "widely-applicable" breast cancer prognostic marker. We propose based on the expression of stromal Cav-1, that breast cancer patients could be stratified into high-risk and low-risk groups. High-risk patients showing an absence of stromal Cav-1 should be offered more aggressive therapies, such as anti-angiogenic approaches, in addition to the standard therapy regimens. Mechanistically, loss of stromal Cav-1 is a surrogate biomarker for increased cell cycle progression, growth factor secretion, "stemness", and angiogenic potential in the tumor microenvironment. Since almost all cancers develop within the context of a stromal microenvironment, this new stromal classification system may be broadly applicable to other epithelial and non-epithelial cancer subtypes, as well as "pre-malignant" lesions (carcinoma in situ).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1538-4101
1551-4005
1551-4005
DOI:10.4161/cc.8.11.8544